Molecular Biomarker

Molecular Biomarker refers to a measurable biological molecule indicating normal physiological processes, pathogenic processes, or responses to therapeutic interventions, typically derived from DNA, RNA, proteins, metabolites, or epigenetic modifications. Biomarkers can serve multiple roles including diagnostic confirmation, prognosis prediction, patient stratification, pharmacodynamic monitoring, and safety assessment, measured in tissues, blood, urine, or other biofluids.

The biopharmaceutical industry relies heavily on molecular biomarkers to enable precision medicine, improve clinical trial success rates, and support regulatory decision-making. Biomarker-guided development identifies patient populations most likely to respond to targeted therapies, such as selecting oncology patients based on tumour mutations or receptor expression. Pharmacodynamic biomarkers confirm target engagement and pathway modulation, supporting dose selection and mechanistic validation. Safety biomarkers detect early organ injury signals, improving risk management and patient monitoring. Companion diagnostics often co-develop with targeted therapies, requiring analytical validation and clinical evidence demonstrating biomarker utility. As omics technologies expand and real-world data integration strengthens, molecular biomarkers continue transforming drug development through improved patient selection and earlier decision-making.